Partners Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. are pushing aggressively to expand the antibody-drug conjugate Adcetris (brentuximab vedotin) in new lymphoma indications. The first of three ongoing Phase III trials has read out positively, but late-stage studies are continuing in what are expected to be the larger commercial opportunities.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?